368 related articles for article (PubMed ID: 12097280)
41. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death.
Fu Q; Kim SW; Chen HX; Grill S; Cheng YC
Mol Pharmacol; 1999 Apr; 55(4):677-83. PubMed ID: 10101025
[TBL] [Abstract][Full Text] [Related]
42. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
43. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
44. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Kubota N; Kanzawa F; Nishio K; Takeda Y; Ohmori T; Fujiwara Y; Terashima Y; Saijo N
Biochem Biophys Res Commun; 1992 Oct; 188(2):571-7. PubMed ID: 1332703
[TBL] [Abstract][Full Text] [Related]
45. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments.
Pantazis P
Clin Cancer Res; 1995 Nov; 1(11):1235-44. PubMed ID: 9815917
[TBL] [Abstract][Full Text] [Related]
46. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Perego P; Cossa G; Tinelli S; Corna E; Carenini N; Gatti L; De Cesare M; Ciusani E; Zunino F; Luison E; Canevari S; Zaffaroni N; Beretta GL
Biochem Pharmacol; 2012 Jan; 83(1):27-36. PubMed ID: 21978643
[TBL] [Abstract][Full Text] [Related]
47. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.
Lotito L; Russo A; Bueno S; Chillemi G; Fogli MV; Capranico G
Eur J Pharmacol; 2009 Jan; 603(1-3):29-36. PubMed ID: 19094980
[TBL] [Abstract][Full Text] [Related]
48. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.
Sugimoto Y; Tsukahara S; Oh-hara T; Liu LF; Tsuruo T
Cancer Res; 1990 Dec; 50(24):7962-5. PubMed ID: 2174738
[TBL] [Abstract][Full Text] [Related]
49. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Beidler DR; Cheng YC
Mol Pharmacol; 1995 May; 47(5):907-14. PubMed ID: 7538195
[TBL] [Abstract][Full Text] [Related]
50. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
51. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
52. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
53. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
54. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
55. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.
Horie K; Tomida A; Sugimoto Y; Yasugi T; Yoshikawa H; Taketani Y; Tsuruo T
Oncogene; 2002 Nov; 21(52):7913-22. PubMed ID: 12439742
[TBL] [Abstract][Full Text] [Related]
56. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
57. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.
Konkimalla VB; Efferth T
Biochem Pharmacol; 2010 Jul; 80(1):39-49. PubMed ID: 20206609
[TBL] [Abstract][Full Text] [Related]
59. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
60. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
